# Index


**A**

Abetalipoproteinemia,23,26ff.,313,457,572, 579ff.,580
Acanthocytosis,26
Acetylsalicylic acid,393
Acetylserotoninmethyltransferase,291,296,297, 299,300,301
Acid phosphatase,281,286,287,381
Acuity luminance function,129ff.
Adaptation,115ff.,137ff.,148,149,175
Age
    variability of RP-onset
Ageing,39,282,285,287,289,291,435,450,471ff.
α-interferon,316
Albinos,435
Allografts,509
Alpha-amino-isobutyric acid,24
Alpha-crystallin,515
Alpha-Linolenate/Linolenate-Balance,563ff.
Apolipoprotein E,575ff.,579ff.
    genetic variation,575ff.
    Isoelectric focusing of,576
    phenotypes,576
Apoliprotein E2,575ff.
Alström syndrome,457
Amphetamine,
Amplitude,99ff.
Angiography,368
Angiotensin converting enzyme,520
Animal,303
Animal models,18,56,381ff.,397ff.,405ff., 411ff.,417ff.,445ff.,449, 467ff.,471ff.
Anosmia,60
Antibodies,490
Antiretinal antibodies,493
Antiserum
    calmodulin,361
    guanylate cyclase,361
Arachidonic acid low level in x-linked RP,559
Arginine,14,24
AR-L 115 BS,95ff.,155ff.
    effects on Panel D-15,157
    effects on FM 100 Hue Test,157
Arterially perfused cat eyes,96
Arterioles, retinal,30
Ataxia,59,75
ATP,359
    ase,271,275,276,278
        activity,271
        magnesium dependent,274,275
        proton,271,278
Atrophia gyrata,
    see Gyrate atrophy
Audiology,66
Audiometry,546
Auditory system,75,379,435ff.,457,543
Autoaggressive disorders,13
Autoantibodies,491,519,543
    inner ear structures,543,547
    ocular,521
Autoantigen,480
Autoimmune disease,316
    complement,523
    Fc-receptors,523
Autoimmune disorders,513
Autoimmunity,497,513
Autoimmunopathies,491
Autophagy,468
Autoradiography,309,374,397
Autoreactivity,518
    cellular,520
    physiological,520
Autosomal dominant RP
    Carriers, apparently uneffected,119
    diffuse visual loss,174
    Heterogeneity,115ff.
    Incomplete penetrance,115ff.
    Red blood cell osmotic fragility,116
    Regional pattern of visual loss,174
    two distinct forms, differentiated by fundus reflectometry, 169ff.
    early disease pattern in...,116
        diffuse pattern,116
Avidin-biotin-peroxidase complex technique (ABC),481

**B**

Barium,438
Base sequence variation,221
Basic mycline protein,492
Bassen-Kornzweig,579ff.
Bechterew's disease,492
Behcet's disease,492,510,512,521,539
Beta crystallin,515
Biettische kristalline Fundusdystrophie,74
Biochemistry,5,63,435ff.
Biopsy
    muscle,79
Birds,293,296,297,300
Birdshot choroidopathy,515
Biochemical studies,303
Biochemistry,323

Biopterin,294,296,301
Bleaching,346
Blindness,303,304
Blood retinal barrier permeability,193ff.
Blood vessels,287,370
Blue perimetry,12
Blue sensitive cones,98,155ff.
Blue yellow defect in pathologic myopia,146
B-Lymphocytes,479,490
Bone spicule,369
British Retinitis Pigmentosa Society Eye Donor Scheme,283
Bronchitis and RP,268ff.
Bruch's membrane,373,388,419

C

Ca-antagonists,339,360
Ca-channels,354
Cadmium,439
Caffeine,96
Calcium,265ff.,353,439
$Ca^{++}$-ions,353,354
  and increase in cyclic GMP,265ff.
Calcium metabolism,162
  in rods and blue sensitive cones,162
Calliphora erythrocephala,325
Calliphora mutant,327
Calmodulin (CaM),353,355,357,358,362
  antisera,356
Canine retinal atrophy,96,449ff.
Capillaries,417
Carboxypeptidase,345,346
Cardiac dysrythmias,75
Cardiomyopathy,65
Carotenoids,325
Carrier detection
  in x-linked Retinitis pigmentosa,207
Carriers,10
Cataracts,30,304,312
Cation,195,339,362
Cats,445
Cell culture,281
Cell death,283
Cell mediated immune reactions,480,520
Cellular retinal-binding protein,314
Central scotoma,543
Central vision,271
Centromere heteromorphism,205ff.
Cerebral sclerosis,65
Cerebrospinal fluid,59
Ceroid-lipofuscinosis,405ff.446,449,453
Choriocapillaris,419
cGMP,96,99
Chicken,297
Chimeric animals,310
Chloroquine,471ff.
Cholesterol,571ff.
  HOL,571ff.
  LDL,571ff.
Choriocapillaries,281
Chorioretinal degeneration,137ff.,312,367ff.,435
Chorioretinitis,537
Choroid,73,303,373
Choroideremia,155ff.,199,200,203,211ff.,215ff.239ff.,245ff.,304,317
  early diagnosis by cloned DNA sequence,213
  gene locus,203
  mimicked by myopic choroidosis,137ff.
Chromatic adaptation,98
Chromatography,296
Chromosome yumping,233
Chromosome walking,225ff.
Chylomicrons
  deficiency of,579
Cilia,265ff.,353,362,399,400
  9+0 type,354
  9+2 type
Cilia of Paramecium,265ff.
Ciliary body,438
Ciliary processes,517
Circadian rythms,467ff.
Circulating immune complexes,521
Class II antigens,479
Cloned DNA sequences,211ff.
Coated vesicles,329
Colchicin,539
Collie,318
COCKAYNE syndrome,457
Colour vision,312
  in fundus flavimaculatus,83
Colour vision defect,544
Complamine,111
Complement cascade,490,517
Complement factors,498
Complement mediated cytotoxity assay,481
Computer,206,209,274,275
Conconavalin A (Con A),482
Conductance,339
Cone-cone-interaction,137ff.
  in fundus flavimaculatus,85
Cone dysfunction syndromes,11
Cone flicker threshold,137ff.,142
  in fundus flavimaculatus,83
  during dark adaption
    pathologic rise,141,142,148,149
Cone function,137ff.
Cone interaction,155ff.
Cone-rod dystrophy,100,543,553
Cone-rod-interaction,137ff.
Cone specific red-perimetry,544
Cones,31ff.,98,177ff.,271,397ff.
  development,397ff.

histology,397ff.
cone losses,115ff.
Congential stationary nightblindness,54
Conjunctivitis,521
Corticosteroids,539
Cortisol,103
Cotton wool spots,492
Creatine biosynthesis,312
Crisis response
phase model of,585ff.
Crystalline deposits,69
Crystalline fundus dystrophy,69
Crystalline inclusions,75
Culture,281–284,286,287,293,308,362
attachment,285
medium,285
proliferation,285
Cut off filter spectacles,129ff.
C-waves,446
Cyclic AMP,19,155ff.,163,303,311,317
Cyclic GMP
(cGMP),19,305,315,317,339,345,360
cGMP-guanylate cyclase,353
Cyclic GMP phosphodiesterase (PDE),303,306
Cyclic guanosine-monophosphate,293
Cyclic nucleotides,95,318
Cyclic AMP,304
Cyclic GMP,304
defects
Cyclophosphamide,540
Cyclosporins,539
Cystinuria/Cystinosis,457
Cystoid edema,468
Cytoplasmic loop,345
Cytotoxis lymphocytes,539
Cytotoxity
RP monocytes,482

D

Dalmatian dog,405ff.
Dark adaptation,73,84,115ff.,118,119,
137ff.,148,149,175,300,305,312
in autosomal dominant RP,
118,119
in fundus flavimaculatus,83
Deafness
see "auditory system"
Degeneration
light induced,325
Deletion mapping,225ff.,227ff.,242
Dendritic cells,480
Densitometer
imaging,177ff.
small field,177ff.
Densitometry,54,177ff.
Density,177ff.
Deprivation,585ff.
Determinants,490
Development,397,417,450
Diabetes,303,450
Diltiazem,339,342
Disc assembly,30,315,340
DNA,294,301
DNA banking,239ff.
DNA linkage,215ff.,239ff.,245ff.,316
DNA probes,199ff.,209ff.
DNA
sequences, cloned,205ff.,211ff.,217ff,231
in x-linked Retinitis
pigmentosa,205ff.
DNA synthesis,282
Docosahexaenoic acid,557ff.
low plasma levels in x-linked RP,557
Dog,446,449ff.
Domperidone,103
Donor eye program,18,252,253
Donor eyes,251ff.,283,285–287
Dopamine,103,467
Drosophila,325
Drug therapy,537
Drugs,467,471ff.
Drusen,373,424
Duchenne muscular dystrophy,225ff.
Dystrophic rats,275,276

E

Ear
see "auditory system"
Early diagnosis,217ff.
Early receptor potential,189ff.
recording in Retinitis pigmentosa
EGTA,355,360
Electromyography,61
Electron microscopy,327,436,472
Electrooculography see EOG
Electrophysiology,5,445,450
in fundus flavimaculatus,83
Electroretinography see ERG
Endolymph,441
Endolymphatic duct,547
Endonucleose,218
Endophthalmitis,538
Endothelial cells,480
Endothelium,510
Endotoxin,511,513,516
English setters,405ff.
Enkad,111
Enzyme activity,65,381ff.,389,430
Enzyme deficiency,23,55
EOG,111
in atrophia gyrata,24
in crystalline fundus dystrophy,73
in fundus flavimaculatus,84
rise after A2-L 115 BS,162
ERG,30,95,11,142,146,161,162,189ff.,271,272,

278,309,312,313,325,331,379,412,544,563ff., 565,566,568,569
in atrophia gyrate,24
in carriers,121ff.
in crystalline fundus dystrophy,73
in fundus flavimaculatus,84
in pathologic myopia,142
c-wave,460
PDE inhibitors,95ff.
ERP alterations in Retinitis Pigmentosa and morphological changes in photoreceptors,189ff.
ERP in Retinitis Pigmentosa,189ff.
Essential fatty acids,564,579ff.
Estradiol,103
Experimental allergic encephalitis,515
Experimental allergic uveitis (EAU),510,514,515
Cyclosporin-A,515
Eye donor scheme see Donor eye program

F

Fat malabsorption,579ff.
Filters,10
Fingerprint bodies,406
Flecked retina syndromes,83
Flicker,121ff.,137ff.,142,148,149
ERG
in pathologic myopia,142
studies
in carriers of x-linked RP,121ff.
in RP patients,121ff.
Fluoresceine angiography,69,137ff.,317,451
in fundus flavimaculatus,87
in hereditary myopia assoziated with choroidal degeneration, 137ff.,141-146
Fluorescence,291,293,298
Fluorescent light,327,334
Fluorophotometry,193
Flynn-aird syndrome,457
Foetus,283
Foveal reflex,30
Free radicals,282,287,289,441
Freund's complete adjuvant,514
Friedreich's ataxia,457
FSH,103
Fundus,544
Fundus flavimaculatus,83,85
Fundusreflectometry,5,169ff.,181ff.
by high sensitivity TV,170ff.
distinguishing RP subtypes by,181ff.
in Retinitis pigmentosa,184,185

G

Gamma crystallin,515
Gamma interferon,498,510,521
GDP,345
Gene activity,272
Gene locus in choroideremia,203
Genetic counselling,215ff.
Genetic disorders,217ff.
Genetic mapping,199ff.,212,216,225
Genetic register,245
and GNA linkage studies in x-linked RP,246
data protection,247
Genetics,5,17,59,445
gene penetrance,115
Glaucoma,55,482
in Kearns Sayre syndrome,76
Glutamate,24
Glycolysation,374
GMP, cyclic,256ff.
G-protein,306
Growth factors,304
GTP,306,345,359
Guanylate cyclase (GC),265ff.,306, 315,356,358
in cilia of paramecium,265ff.
Gyrate atrophy,14,23,24ff.,304,311,457

H

Hallervorden-Spatz disease,457
Hallgren syndrome,457
HDL cholesterol,572
Hearing
see "auditory system"
Hearing impairment and RP,268ff.
Hemeralopia
see "night-blindness"
Hereditary chorioretinal degeneration,313
see also choroideremia, gyrate atrophy, RP
Herpes zoster,520
Heterochromia complicata Fuchs,538
Heterogeneity,223
Histocompatibility,492
Behcet's disease,519
birdshot choroidopathy,518
glaucomatocyclitic crisis,519
sympathetic ophthalmia,519
uveitis,518
black Americans,519
Histopathology,18,317,367ff.,417ff.
Histoplasmosis,516
HLA,487,512,518
HLA class I antigens,510
HLA class II antigen,490,510
Hyperlipidaemia,557ff.

Hypo-beta-lipoproteinaemia,572
Hypocholesterolaemia
in late onset autosomal dominant RP,560
Hooft syndrome,457
Hormones,304
HPLC,294
Hydroxymethylpterin,296,301
Hypochromic cyclitis,508
Hypogalactia,104
Hypothalamus,103ff.

I-J

Ichthyosis,61
IFN-gamma,482
Imaging fundus reflectometry,170ff.
Immune complexes,490,492,498,507,517,522
Immune complex vasculitis,490,510
Immune responses,479,510,514
Immuno histochemistry,431
Immunofluorescence,498
Immunofluorescence technique,481,550
inner ear,546
Immunopathology,489,507
Immunosuppressive therapy,538,549
Impairment, visual,585ff.
Implicit time,95ff.
Infection
latent,520
Infertility and RP,269
Inheritance,23,54,405
Intensity-response functions,96
Interferon (IFN),479,490
Interleukin 1/3,490
Interneurons,331
Interphotoreceptor matrix,475,516
Interphotoreceptor retinoid-binding protein (IRBP),313,317,504,513516
Intoxication,467ff.
Intraocular inflammation,538
in vitro studies
retinal metabolism,367ff.,374ff.
Iodoacetic acid,430
Ions
binding and releasing,435
Iridocyclytis,537
Iris,517
Irish setter,96,272,307,360
Iritis,537
Irvine-Gass syndrome,414

K

Kartagener syndrome,457
Kearns-Sayre syndrome,23,75,457
Keratitis,521

L

LAMMA (laser induced mass microprobe technique),435ff.
Lamellae,405ff.
Langerhans cells,480,490
Lanthanum,353
Laser microprobe mass analysis (LAMMA),115ff.
Laser scanning ophthalmoscope,177ff.
Latex microspheres,281,283-287
Laurence-Moon-Bardet-Biedl syndrome,282,283,457
LDL cholesterol,572
Leber's congential amaurosis of retinal origin,457
Lectin,431
Lens proteins,491,514
LEU 4,498
Leukotrienes,510
Life style,557ff.
Light,292,293,297,301,303
blue,300
colour,300
cyclic GMP,304
green,300,301
intensity,296,298,300
sensitivity,291
Light adaptation,117ff.,305
in autosomal dominant RP,117ff.,217ff.
Light damage,411ff.,467ff
Light scattering,271,274,275,277
intensity,274-276
Light scattering spectroscopy,271,272
absorbance,273
reflection,273
time-intensity profiles,272
Lignac-Fanconi syndrome,457
Linkage,200,205ff.,209ff.,239,245ff.
Linkage analysis
by Elston Stewart algorithm,210
by UPED computer programme,200
Linkage disequilibrium,228
Linkage studies
in x-linked Retinitis Pigmentosa,205ff.
Lipid abnormalities in RP,471ff.,557ff.
Lipids,475,557ff.
Lipofuscine,281-287,579ff.
Lipoprotein,,557ff.,563ff.,571ff.,575ff.
serum concentrations in RP
Lues,491
Lipopigments,405ff.,449
Lithium,467
Luminance,12
Lymphocytes,519
Lymphocyte blast transformation,497
Lymphokines,316,479,510,540

interferon gamma,486
Lymphocytic chorio meningitis (LCM) virus,518
Lysine,24
Lysosomal diseases
gangliosidoses,405
metachromatic leukodystrophy,405
Niemann-Pick disease,405
Lysosomes,286,289,381ff.,393,418,446,471ff.

M

Macrophage,316,490
inhibition tests,493
Macula,287,289
Maculadegeneration,482
Magnesium,360,438
Mangan,360
MAO-inhibitor,467
Mapping, genetic,199,212
Mast cells,490
Mediators,490,539
Megabase map,225ff.
Melanin,281-287,289,293,412,435ff.
Melanocytes,436ff.
Melanosomes,373
Melatonin,291-293,301
Membranogenesis,281
Mental retardation,75
Metabolic disorders,23ff.,450
Metarhodopsin,325,331,335
Metoclopramide,103
MHC,487,512
MHC geneMicrobiology,5
Microcloning,231
Micro-organisms,489
Microvilli,329
Migration inhibition tests,493
Miniature poodle,309
Mitochondria,23,75
retinal dystrophy,75
Modulation transfer function,121ff.
in carriers of x-linked RP,121ff.,124,126
in RP patients,121ff.
Molecular biology,316
Monoclonal antibodies,485
Monocytes,479,482,490,510
Mouse,56,96
Mucopolysaccharidoses,457,472
Mueller cells,492
Muscle biopsy,75
Myelin,419
Melatonin,467
Myeloid bodies,460
Myopia, early pathologic,137ff.
Myopia, hereditary,137ff.
associated with choroidal degeneration,137ff
spectral sensitivity,137ff.
fluoresceine angiography,137ff.
dark adaptation,137ff.
cone flicker threshold,137ff.
Myopia, pathologic
blue yellow colour defect,146
Myotonic dystrophy,457

N

Neovascularization,55
Nephronophthisis,457
Nerve fibers,423
Neural retina,310
Neurodegenerative diseases
neuronal ceroid lipofuscinosis,405
Refsum's disease,405
Neuromuscular abnormalitiy,26
Neuropathy
in a-beta-lipoproteinaemia,579ff.
Neuropeptides,518
Neurotransmitters,304,374,467
Night-blindness,29,31,54,368,451
Night vision,24
Norrie disease,211ff.
Nucleotide,318,319,360
Nyktalopia
see "night-blindness"

O

Ocular antigens,513
Ocular autoimmune disease,507
Ocular immune vasculitis,511
Ommatidia,327
Ophthalmoplegia,75
Opsin,334,335,504,513,516
Optic neuritis,515
Ornithine,14,23,312
Ornithine aminotransferase,304,312
carriers,312
Oxalosis,459
Oxygen,432

P

P III responses,98
Panophthalmitis,538
Panuveitis,538
Papaverine hydrochloride,96
Paramecium,265ff.,353,356,361
Pathomorphology
see "Histopathology"
PDE-inhibitors,95ff.

Pelizaeus–Merzbacher disease,457
Penetrance,54
Pentobarbital,418
Perimetry
blue stimuli,12
dark adaptation,115ff.
Phagocytosis,281,282,284–286,309,467ff.,483
Phagosomes,286,563ff.,565,567,570
Phase contrast microscopy,283
Phosphatidylethanolamine,563ff.
Phosphatidylserine,563ff.
Phosphenes,157ff.
induced by AR-L 115 BS,156ff.
Phosphodiesterase
(PDE),155ff.,307,345,359,360
Photoactivation,345
Phosphatase activity,431
Phosphocreatine,312
Photocoagulation,55
Photon,345
Photoreceptor cells,315
Photoreceptors,19,54,271,278,282,305,307,317,
323,325,339,370,381,
397,405ff.,412,417,450,471ff.,492,497,504,544
canine,460
cilium,400
cones
invaginations,400ff.
degeneration,303,307ff.329,468,471
disk shedding,467ff.
drug effects,471
dysplasia,303
length variation,183
membranes,325,397ff.
morphological changes and ERP
alterations,189ff.
morphology,419ff.
nuclei,420
outer segments,307,339
packing density,183
renewal,397ff.
repair processes,468
shedding,400
ultrastructure,325
Phototransduction,5,339
Phototoxity,432
Phytanic acid,27,59,63
Pigment,30,271,370
Pigment epithelial cells,56,251ff.,272,303,
405ff.,412,497
canine,460
infoldings,419
lipid-like granules,431
lysosomes,381ff.,431
microvilli,423
migration,431
morphology,419ff.
myeloid bodies,431
phagocytosis,418,431
photochemical effects,468
regenerative changes,431
semicircular inclusions,463
visual cell PE complex,468ff.
Pineal,292,516
Pituitary secretion,103
Platelet activating factor (PAF),540
Polyneuropathy,59
Posner–Schlossmann's syndrome,538
Posterior segment,489
Pristanic acid,64
Progressive rod-cone degeneration,309
Prolactin,511
Precombination fraction,202,203,206,207,211,
212,217ff.,220,242
Prenatal diagnosis
in x-linked Retinitis pigmentosa,207
Prevention,217ff.
Proliferation,417ff.,427
Prostaglandins,510
Protease,345,348
Proton ATPase,271
Pseudo Retinitis pigmentosa,80
Psychology of visual loss,585ff.
Pteridine,291,293,294,297,299,301
Pulsed field electrophoresis,225ff.
Pulsed field gradient electrophoresis,228,229
Pupillary abnormalities,59
Pyrazine-(2,3-d)-pyrimidine,291
Pyridoxine,25

Q

Quail,291,293,296–298,300
Quinine,435

R

Rat,56,103,104,272,381ff.,412,414,417,467,
471ff.
retinal degeneration,310
RCS rats,271,272,275–278,303,310,313,316
rdg B,325
rd-mice (mouse),272,307,318
rdy gene,310
Receptor potentials,305
Recombinant DNA,217ff.
Red blood cell osmotic fragility (in autosomal
dominant RP),116
Refsum's disease,23,27,59ff.,303,457
age of onset,59
dietary treatment,59,65ff.
Regeneration,177ff.
Reissner's membrane,549
Restriction fragment length polymorphism
(RFLP),17,205ff.,218,226
detection on the x-chromosome in

choroideremia–patients and
partners,200
in carriers of choroideremia,199ff.
in choroideremia,200ff.
Retina,289,291,292,296,297,303
human,291
in vitro studies,449
photochemical damage,411
thermal damage,411
toxic effect on the,431
ultrafiltrate,295–298,301
ultrastructural pathology,405ff.
ultraviolet light,412
vertebrate,339
Retinal degeneration,23ff.,75ff.,251ff.,293,
303,304,325,360,417ff.
animal,303
human,303
intervertebrates,325
vertebrates,325
Retinal dysplasia,309
collie,307
Irish setter,307
rd mouse,307
Retinal lipids,563ff.
Retinal morphology,449
Retinal necrosis syndrome,519
Retinal pigment epithelium (RPE),251ff.,
281–285,287,289,292,303,309,312,316,406,
417,435ff.538
abiotrophy,317
culture,311,480
genetic defect,310
in Kearns Sayre syndrome,76
in vitro,483
phagocytosis,310,318
melanolysosomes,315
ultrastructure,317
RPE cells,486
Retinal S-antigen,486,491,513,515
Retinal vasculature,417ff.,425
endothelium,426
pericytes,431
Retinitis pigmentosa
(RP),100,115ff.,121ff.,129ff.,138ff.,169ff.,
181ff.,189ff.,193ff.,205ff.,209ff.,215ff.,
225ff.,245ff.,251ff.,271,281,282,303,304,313,
323,342,360,411ff,453,479,480,486,489,493,
551,553,557ff.,571ff.,575ff.,585
age of onset,31,49,
amplitude in early stage,95ff.
and bronchitis,268
and hearing impairment,268
and infertility,269
and sinusitis,268
animal,303
animal models,304
antiinflammatory drugs,393
anti-retinal antibodies,497
autoantibodies,504
autoradiograms,374ff.
autosomal dominant,17,18,36,51,
115ff.,138,169ff.,174,253,304,
571ff.,573
incomplete penetrance,115ff
and myopia,138
axons
histopathology,373ff.,415
metabolic studies,23ff.,367ff.
optic nerve,374
autosomal recessive,23ff.,30,138,
571ff.,573
and myopia,138
bilateral symmetry,39
blood supply,379
canine species,446
cardiac manifestations,61
cataract,30
cerebral signs,65
characteristics,29ff.
chorioretinal degeneration,367ff.
cilia,315
crystalline deposits,69ff.
data bank,5
deafness,379
development,471
diagnostic techniques,6
diffuse loss,33
disk,30
distribution of rods and cones,370
donor eyes,5,367ff.
electroretinogram,30
enzyme activity,65
etiology,445,457
experimentally induced,445
family history,30
fundus,30
gene,115ff.,225ff.
genetics,17
glaring,12
glycolysation,374
heterogeneity,115ff.
histology,367ff.,411
histopathology,18,369,370
human,303,304,313
hyposmia,60
IgM,493
implicit time,95ff.
intervertebrates,325
intra-familial comparisons
early,115ff.
late onset,14,378
light damage,411ff.
lipid metabolism,10
loss of peripheral vision,304
lues,14
midperipheral ring scotoma,30
mitochondria,75

models,307
morphological studies,445
multiplex,30,36
multiplex cases,121ff.,304
muscular atrophy,60
natural course,29ff.
nerve conduction velocity,61
night blindness,271,304
onset,37,397ff.
optic nerve,367ff.
pathogenesis,99
pathology,316
pathophysiological subtypes,29ff.
patient physician relationship,3ff.
peripheral vision,31
photoreceptors,367ff.
phytanic acid,59,63
pigment epithelium,370,372
pigmentation,30,60
predisposition,54
progression,411ff.
protective glasses,11
protein glycolysation,367ff.
recessive,17,304,381,415,418
regionalized patterns,32
renal failure,379
renewal process,316
research plan,
retina
ultrastructure,315
retinal pigment epithelium
ultrastructure,315
scotoma,304
secondary,13,405,457,471ff.
sector type,313
sectorial,368
sex-linked,304
sex-linked recessive,23ff.
simplex,30,36,121ff.,304
sine pigmento,60
sporadic, isolated,572,573
systemic diseases,23ff.
technology,3
therapy control,56,66
tissue studies,5
type 1/type 2 distinction,36
vasculature,417ff.
vertebrates,325
visual field,30ff,46ff.
visual field loss,46ff.
vitamin A therapy,26
vitamin E therapy,26
vitreous degeneration,30
x-linked,10,18,30,121,138,193ff.,
205ff.,209ff.,211ff.,215,222,245ff.,
253,557ff.,571ff.,573
carrier detection,207
carriers,193
fluorophotometric evaluation
of carriers
gene, genetric markers,316
low load of arachidonic
acid,559
low levels of docosa hecaenoic
acid,557ff.
and myopia,138
prenatal diagnosis,207
Retinochoroiditis,516,537
Retinoid
isomerization,313
Retinopathy,579ff.
Retinoschisis (x-linked),211
Retinotoxic drugs,155ff.,436ff.
Rhabdomeric photoreceptors,325
Rheumatoid factors,498
Rhodopsin,100,171ff.,275,305-307,331,
333,334,339,345,346,498,504, 513,516
loss of,54
and visual threshold elevation,173,174
in two types of autosomal
dominant RP,173ff.
Ribosomes,419
RNA synthesis,374
Rod-cone interaction,84
Rod function,137ff.
Rod outer segments,258,261,265ff.
see ROS
Rods,31,169ff.,177,271,271,276,287,317,397ff.
bovine,277
development,397ff.
histology,397ff.
evaginations,398ff.
outer segment,397
regional loss,115
ROS (rod outer segments),271,274-278,281,
287,304,306,309,310,339,341,345,353,359,361
adaptation,275
bovine,271,274,283,286,493
cyclic GMP,304
frog,305
phagocytosis,311,315
renewal,309
rhodopsin,273
transduction,275,293
RPE cells,251ff.
culture,251ff,253,256
post mortem time,253
membranogenesis,251ff.,260-262
microvilli,251ff,259-261
phagocytosis,251ff.,256-262
RPE cell culture,251ff.
depigmentation,254
lipofuscin,255
phagocytosis,256-262
transepithelial transport,256

S

Saccus endolymphaticus,551
S-antigen,480,498,504,510
Saturation
Scanning laser opthalmoscope,177ff.
Scleritis,492
Scotoma,29ff.,544
Sensorineural hearing loss,553
Setters,318,446
Sinusitis an RP,268ff.
Skeletal malformations,59
Skin changes,59,61
Skin fibroblasts,24,64
Sodium conductance,305
Spectral
sensitivity,32,137ff.,147,148,155ff,160,164,165
in fundus flavimaculatus,83,89
in hereditary myopia associated with choroidal degeneration, 137ff.,141,146-148
Spermatozoa,18
Spinocerebellar ataxia
in abetalipoproteinaemia,580
Spinocerebellar degeneration,579ff.
Standing potential,446
Stargardt's disease,84
Steatorrhea,26
Storage diseases,13
Stria vascularis,549
Subretinal space,417,419
Suppressor T cells,519
Sympathetic ophthalmia,515,538

T

Tapetoretinal degeneration
crystalline deposits,73
metabolic,457
Tapetoretinal disorder,543
Testosterone,103
Tetrahydrobiopterin,291
Tetrahymena,353,356-358,361
Theophylline
Therapeutic approaches,23
Therapy,217ff.,579ff.
Thermal damage,411
Thermolysin,345,346
Thresholds,33
Thyroiditis,480
Thyroid epithelial cells,480
Tilorone,471ff.
T-lymphocytes,316,480,486,490
Tolerance,509
Toxic drugs,436ff.
Toxoplasma,515,516
Toxoplasmosis,450,491
Trace element distribution, retinal,195,435ff.
Transducin,306,345
Transduction,339
Transfer factors,490
Transient tritanopia,10,137ff.,141,146-148,155ff.,158
in fundus flavimaculatus,83
in hereditary myopia associated with choroidal degeneration,141 146-148
loss in choroideremia,165
under AR-L 115 BS,158,161
Translocation mapping,227
TRH,103
Triamterene,292
Triglycerides,572,576
Trimethyllysine,356,359
Turner syndrome,457
Type II musclefiber atrophy,312

U

Usher's syndrome,17ff.,65,435,457,543
Uvea
anatomy,509
Uveal pigment antigens,492
Uveitis,489,491,497,507,539
ankylosing spondylitis,492
anterior,521,522
autoantibodies,504
Behcet's syndrome,492
collagen diseases,492
candidiasis,518
causes,511
granulomatous,491
immunopathology,524
incidence,508
infectious agents,511
klebsiella pneumoniae,492
lens-induced,538
panuveitis,521,522
phacoantigenic,491
posterior,521,522
rheumathoid arthritis,492
serum disease,491
sympathetic ophthalmia,491
systemic lupus erythematosus,492
therapy,508
Vogt-Koyanagi-Harada syndrome (VKH),491

V

Vasculature,417ff.
Vasculitis,511,521
Vasodilators,111
Verhoeff's membrane,424
Visual acuity,73
Visual cycle,314

Visual field,10,29ff.,33,46ff.,115ff.
age relation,39
in fundus flavimaculatus,83
planimetric measures,39
RP subtypes,29
Visual field eccentricity,33
Visual function,271
Visual impairment in RP
changes in personal value systems,590
changes in sensory perception,589
Visual pigment,177ff.,301,339,412
examined by fundus reflectometry, 181ff.
Visual threshold
quantum catch model,183,185
Vitamin A,272,311,313,579ff.
therapy,26
delayed dark adaptation,174,175
differentiation from autosomal dominant RP,169ff.
Vitamin $B_6$,24
Vitamin E,26,579ff.
Vitiligo,13,553
Vitreous,30,304,368
Vogt–Koyanagi–Harada syndrome,14,515

W

Waardenburg's syndrome,435

X

Xanthinoxydase,292
Xanthopterin,294,296,298,299,301
Xenopus laevis,308
X-linked,317
X-linked Retinitis pigmentosa
carrier detection,207,211ff.
carriers,193
early diagnosis by cloned DNA sequences,211ff.
linkage studies,205ff.
low level of arachidonic acid,559
low levels of docosahexaenoic acid,557ff.
prenatal diagnosis,207
X-ray analyzer

Y

Yersinia enterocolitica,523

Z

Zinc,439